-
-
VITRAKVI
- QTY 28
- 100 MG
- Capsule
LAROTRECTINIB (lar oh trek ti nib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat neurotrophic receptor tyrosine kinase gene fusion-positive solid tumors.
Change Location
Set Price Drop Alert for:
VITRAKVI
- QTY 28
- 100 MG
- Capsule
More Ways to Save On:
VITRAKVI
- QTY 28
- 100 MG
- Capsule
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
- Change Form
Medicine Chest
VITRAKVI Lifestyle Interactions
-
Larotrectinib 100mg, Oral capsule
• Interaction: Grapefruit juice• Severity: Major• Notes for Consumers: Do not eat grapefruit or drink grapefruit juice while taking Larotrectinib. Grapefruit can increase the amount of Larotrectinib in your blood and increase the risk of side effects from Larotrectinib including tiredness, nausea, vomiting, dizziness, cough, constipation, diarrhea, dark yellow or brown urine, general ill feeling or flu-like symptoms, light-colored stools, right upper belly pain, or yellowing of the eyes or skin.• Notes for Professionals: Advise patients to avoid grapefruit or grapefruit juice while taking larotrectinib. Coadministration may increase larotrectinib exposure resulting in treatment-related adverse effects. Larotrectinib is a CYP3A4 substrate; grapefruit is a strong CYP3A4 inhibitor. Coadministration of a strong CYP3A4 inhibitor increased the AUC of larotrectinib by 4.3-fold in a drug interaction study.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
